Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

Indoleamine 2,3-dioxygenase (IDO) is generally considered to be immunosuppressive but recent findings suggest this characterization oversimplifies its role in disease pathogenesis. Recently, we showed that IDO is essential for tumor outgrowth in the classical two-stage model of inflammatory skin carcinogenesis. Here, we report that IDO loss did not exacerbate classical inflammatory responses. Rather, IDO induction could be elicited by environmental signals and tumor promoters as an integral component of the inflammatory tissue microenvironment even in the absence of cancer. IDO loss had limited impact on tumor outgrowth in carcinogenesis models that lacked an explicit inflammatory tumor promoter. In the context of inflammatory carcinogenesis where IDO was critical to tumor development, the most important source of IDO was radiation-resistant non-hematopoietic cells, consistent with evidence that loss of the IDO regulatory tumor suppressor gene Bin1 in transformed skin cells facilitates IDO-mediated immune escape by a cell autonomous mechanism. Taken together, our results identify IDO as an integral component of ‘cancer-associated’ inflammation that tilts the immune system toward tumor support. More generally, they promote the concept that mediators of immune escape and cancer-associated inflammation may be genetically synonymous.

[1]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[2]  B. Baban,et al.  Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.

[3]  C. L. Costantino,et al.  Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. , 2009, Journal of the American College of Surgeons.

[4]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[5]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[6]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[7]  G. Prendergast,et al.  Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. , 2010, Cancer research.

[8]  Stefan Schneeberger,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  K. Shirey,et al.  Synergistic Transcriptional Activation of Indoleamine Dioxygenase by IFN-γ and Tumor Necrosis Factor-α , 2003 .

[10]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[11]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[12]  Minshan Chen,et al.  Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[13]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[14]  Hiroyasu Ito,et al.  Serum concentration of L‐kynurenine predicts the clinical outcome of patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2010, European journal of haematology.

[15]  G. Prendergast,et al.  Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.

[16]  R. Peek,et al.  Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. , 2005, Cancer research.

[17]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[18]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[19]  D. Galas,et al.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.

[20]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[21]  N. Yanaihara,et al.  Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells , 2005, Clinical Cancer Research.

[22]  D. Munn,et al.  The tumor‐draining lymph node as an immune‐privileged site , 2006, Immunological reviews.

[23]  A. Cuenca,et al.  Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. , 2001, Blood.

[24]  B. Pockaj,et al.  Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO1 , 2006, The Journal of Immunology.

[25]  Y. Shimoyama,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma , 2009, Clinical & Experimental Metastasis.

[26]  G. Hur,et al.  The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells , 2009, Journal of immunotherapy.

[27]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[28]  H. Schreiber,et al.  The role of stroma in immune recognition and destruction of well-established solid tumors. , 2006, Current opinion in immunology.

[29]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[30]  K. Shirey,et al.  Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase in immune suppression and cancer. , 2007, Current cancer drug targets.

[32]  S. Mamidipalli,et al.  Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity , 2009, Pharmacogenetics and genomics.

[33]  P. Scherle,et al.  Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.

[34]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[35]  J D Kemp,et al.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow , 1991, The Journal of experimental medicine.

[36]  G. Prendergast,et al.  Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. , 2007, Cancer research.

[37]  G. Prendergast,et al.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.

[38]  L. Jermiin,et al.  Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.

[39]  G. Prendergast,et al.  Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. , 2007, Cancer research.

[40]  D. Fuchs,et al.  Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients , 2006, Dermatology.

[41]  E. Jaffee,et al.  Cancer immunologists and cancer biologists: why we didn't talk then but need to now. , 2007, Cancer research.

[42]  H. Kajiyama,et al.  Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer , 2006, British Journal of Cancer.

[43]  D. Munn,et al.  Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancy , 2001, Nature Immunology.

[44]  T. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment , 2007, Clinical Cancer Research.

[45]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[46]  O. Hayaishi,et al.  Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.